The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ERIC 2020 | COVID-19 in the GAIA/CLL13 trial
Barbara Eichhorst, MD, University Hospital Cologne, Cologne, Germany, discusses how COVID-19 has impacted the GAIA/CLL13 trial (NCT02950051). Between March and April 2020, 7 patients in the clinical trial tested positive for COVID-19. Of the 7 patients, 2 died. However, in the recent resurgence of COVID-19, no patients involved in the trial have tested positive for the virus. This is the first analysis of chronic lymphocytic leukemia (CLL) patients receiving venetoclax combination therapy as a first-line treatment. This interview took place during the European Research Initiative on CLL (ERIC) International Virtual Meeting 2020.
